Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancer

16 Mar 2020

Abstract excerpt

Abstract Polybromo-1 (PBRM1) gene is a promising biomarker for immunotherapy in clear cell renal cell carcinoma. But to our knowledge, the frequency and clinical relevance of PBRM1 mutation in lung cancer remain unknown. We conducted a retrospective study to evaluate the prevalence of PBRM1 mutation and its correlation with preliminary response to immunotherapy in non-small cell lung cancer (NSCLC). Our results...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Immunotherapy and Biomarkers
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32195359
DOI: 10.1038/s41698-020-0112-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancerPMID 32195359Read ↗

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancersSemantic proximity Read ↗

Significance of PBRM1 mutation in disease progress and drug selection in clear cell renal cell carcinoma.Semantic proximity Read ↗

Decreased PBRM1 expression predicts unfavorable prognosis in patients with clear cell renal cell carcinomaSemantic proximity Read ↗

<i>PBRM1</i> loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinomaSemantic proximity Read ↗

Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencingSemantic proximity Read ↗

Loss of PBRM1 expression is associated with renal cell carcinoma progression.Semantic proximity Read ↗

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.Semantic proximity Read ↗

PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.Semantic proximity Read ↗

PBRM1 and VHL expression correlate in human clear cell renal cell carcinoma with differential association with patient's overall survival.Semantic proximity Read ↗

Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinomaSemantic proximity Read ↗

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.